ILF2 is a regulator of RNA splicing and DNA damage response in 1q21-amplified multiple myeloma M Marchesini, Y Ogoti, E Fiorini, AA Samur, L Nezi, M D'Anca, P Storti, ... Cancer cell 32 (1), 88-100. e6, 2017 | 142 | 2017 |
Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome S Colla, DST Ong, Y Ogoti, M Marchesini, NA Mistry, K Clise-Dwyer, ... Cancer cell 27 (5), 644-657, 2015 | 115 | 2015 |
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy I Ganan-Gomez, H Yang, F Ma, G Montalban-Bravo, N Thongon, ... Nature medicine 28 (3), 557-567, 2022 | 44 | 2022 |
A thrombin-PAR1/2 feedback loop amplifies thromboinflammatory endothelial responses to the viral RNA analogue poly (I: C) S Subramaniam, Y Ogoti, I Hernandez, M Zogg, F Botros, R Burns, ... Blood Advances 5 (13), 2760-2774, 2021 | 16 | 2021 |
Role of thrombomodulin expression on hematopoietic stem cells S Basu, HPH Liang, I Hernandez, M Zogg, B Fields, J May, Y Ogoti, ... Journal of Thrombosis and Haemostasis 18 (1), 123-135, 2020 | 6 | 2020 |
Cell-type specific mechanisms of hematopoietic stem cell (HSC) expansion underpin progressive disease in myelodysplastic syndromes (MDS) and provide a rationale for targeted … I Ganan-Gomez, A Alfonso, H Yang, A Santoni, V Marchica, E Fiorini, ... Blood, The Journal of the American Society of Hematology 132 (Supplement 1 …, 2018 | 5 | 2018 |
The role of Chip-related DNA damage response dysfunction in therapy-related myeloid neoplasms AA Pierola, M Marchesini, K Takahashi, I Gañán-Gómez, E Fiorini, Y Ogoti, ... Blood 128 (22), 958, 2016 | 2 | 2016 |
Hematopoietic Architecture of MDS before and after Progression Reveals Two Biologically Distinct Disease Subtypes I Gañán-Gómez, A Alfonso, Y Ogoti, H Yang, G Montalban-Bravo, ... Blood 128 (22), 4310, 2016 | 1 | 2016 |
Effect of azacytidine on the hematopoietic stem and progenitor cell compartments of MDS mouse models: unveiling the mechanisms of remission and relapse I Gañán-Gómez, Y Ogoti, M Marchesini, Y Wei, H Yang, S Jiang, N Bao, ... Blood 126 (23), 2852, 2015 | 1 | 2015 |
Telomere Damage Maintains Hematopoietic Stem Cells (HSCs) in an Activated Metabolic State, Which Compromises Their Self-Renewal Capability A Santoni, E Fiorini, FD Lay, M Marchesini, Y Ogoti, C Jackson, A Rose, ... Blood 132, 174, 2018 | | 2018 |
ILF2-YB1 INTERACTION MODULATES RNA SPLICING TO INDUCE RESISTANCE TO DNA-DAMAGING AGENTS IN 1Q21-AMPLIFIED MULTIPLE MYELOMA M Marchesini, Y Ogoti, E Fiorini, M D'Anca, P Storti, L Nezi, M Samur, ... HAEMATOLOGICA 102 (Suppl 2), 102-103, 2017 | | 2017 |
Identification of the Specific Hematopoietic Stem Cell Populations Responsible for Failure to Hypomethylating Agents in Myelodysplastic Syndromes I Ganan-Gomez, A Alfonso, Y Ogoti, H Yang, G Montalban-Bravo, AC Yu, ... Leukemia Research 1 (55), S34-S36, 2017 | | 2017 |
ILF2-YB1 Protein Interaction Modulates RNA Splicing to Induce Resistance to Chemotherapy in High Risk Multiple Myeloma M Marchesini, Y Ogoti, E Fiorini, M D'anca, P Storti, L Nezi, MK Samur, ... Blood 128 (22), 359, 2016 | | 2016 |
Telomere Dysfunction-Induced DNA Damage Drives Hematopoietic Stem Cell Fate M Marchesini, Y Ogoti, I Ganan-Gomez, Y Wei, CE Bueso-Ramos, ... Blood 126 (23), 1156, 2015 | | 2015 |
A Mouse Model of Telomere Dysfunction Recapitulates Hallmark Features of Human Myelodysplastic Syndrome S Colla, D Ong, Y Ogoti, M Marchesini, N Mistry, K Clise-Dwyer, P Storti, ... Blood 124 (21), 523, 2014 | | 2014 |
ILF2 Is Upregulated by 1q21 Amplification in Multiple Myeloma M Marchesini, Y Ogoti, E Fiorini, AA Samur, L Nezi, M D’Anca | | |
Study of the Effect of Azacytidine on the Hematopoietic Stem and Progenitor Cell Compartments of MDS Patients and Mouse Models I Gañán-Gómez, Y Ogoti, M Marchesini, S Jiang, N Bao, K Clise-Dwyer, ... | | |